Sign In
Buy AORT
$26.83
-0.84 (-3.04%)
At Close: Jul 31, 2026
3 Earnings All-Stars With More Room to Run
08:00am, Wednesday, 03'rd Jul 2024
Earnings are essential to determining which stocks will outperform. Unsurprisingly, earnings outperformers also see strong price appreciation.
Artivion Amends Agreements with Endospan
04:05pm, Monday, 01'st Jul 2024
Provides Endospan with $25 million of Additional Debt Funding to Obtain FDA Approval for NEXUS Upfront Payment Associated with Purchase Option Reduced to $135 million, inclusive of loan off-set, and $
Data-Driven Growth Fuels More Upside For Overlooked Artivion
05:01pm, Friday, 21'st Jun 2024
Artivion, Inc. has continued to log double-digit revenue growth with contributions from diverse assets including its stent grafts, heart valves, and cryopreserved tissue grafts. Positive post-approval
Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue?
10:17am, Wednesday, 08'th May 2024
Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Artivion, Inc. (AORT) Q1 2024 Earnings Call Transcript
10:47pm, Monday, 06'th May 2024
Artivion, Inc. (NYSE:AORT ) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Eileen Martin - Investor Relations Pat Mackin - Chief Executive Officer Lance Berry - Chief Fin
Artivion (AORT) Tops Q1 Earnings and Revenue Estimates
06:21pm, Monday, 06'th May 2024
Artivion (AORT) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.02 per share a year ago.
Artivion Reports First Quarter 2024 Financial Results
04:05pm, Monday, 06'th May 2024
First Quarter Highlights: Achieved revenue of $97.4 million in the first quarter of 2024 versus $83.2 million in the first quarter of 2023, an increase of 17% on a GAAP basis and 16% on a non-GAAP con
5-Year Real-World Safety and Efficacy Data from On-X Aortic Heart Valve Low INR Post-Market Study Demonstrate Even Better Patient Outcomes Than Predicted by the PROACT IDE Study Late-Breaking 30-Day D
Artivion Announces Release Date and Teleconference Call Details for First Quarter 2024 Financial Results
04:10pm, Monday, 22'nd Apr 2024
ATLANTA , April 22, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2024 financial resul
Is Artivion (AORT) Outperforming Other Medical Stocks This Year?
10:46am, Monday, 15'th Apr 2024
Here is how Artivion (AORT) and Cencora (COR) have performed compared to their sector so far this year.
Artivion to Participate in the 23rd Annual Needham Virtual Healthcare Conference
04:10pm, Monday, 01'st Apr 2024
ATLANTA, April 1, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the
Artivion, Inc. (AORT) Hits Fresh High: Is There Still Room to Run?
10:16am, Friday, 29'th Mar 2024
Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Are Medical Stocks Lagging Artivion (AORT) This Year?
10:46am, Thursday, 28'th Mar 2024
Here is how Artivion (AORT) and Cencora (COR) have performed compared to their sector so far this year.
3 Buy-Rated Small Caps Flexing Big Growth
05:31pm, Tuesday, 19'th Mar 2024
Small-cap stocks can be solid considerations for those who can handle a higher level of volatility. Analysts have recently become bullish on these three.
Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024
10:51am, Thursday, 14'th Mar 2024
We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.
